NEUROBLASTOMA

This early-phase trial tested a combination of two oral chemotherapy drugs (irinotecan and temozolomide) plus an antibiotic (cefixime) to prevent diarrhea in 30 children whose high-risk neuroblastoma had come back or resisted previous treatments. The goal was to find the safest d…

This study tested a treatment for children with high-risk neuroblastoma that had come back or not responded to standard therapy. It combined a radioactive drug (MIBG) that targets tumor cells with strong chemotherapy, followed by a stem cell transplant to restore healthy blood ce…

This study tested a new treatment for children with high-risk neuroblastoma, a type of cancer. Researchers took the patients' own immune cells (T cells) and modified them to recognize and attack the cancer. Some of these cells were also trained to fight a common virus (EBV) to he…

This study tested a combination of an immunotherapy drug (Hu3F8) and a growth factor (GM-CSF) along with a standard drug (isotretinoin) in 59 children with high-risk neuroblastoma who had already achieved remission. The goal was to see if this treatment could prevent the cancer f…

This early-phase study tested a daily pill called lorlatinib in 65 children and young adults with a type of nerve cancer (neuroblastoma) that had come back or not responded to treatment. The drug targets a specific genetic change (ALK mutation) found in some tumors. The main goal…

This early-phase study tested a targeted radiation therapy (PRRT) in children whose neuroblastoma had come back or not responded to standard treatments. The therapy uses a radioactive drug that seeks out cancer cells. The main goal was to find the safest dose. Only one child took…

This study tested a new type of stem cell transplant in 23 children and young adults with cancers that came back or didn't respond to treatment. The approach uses a special cell filter to speed up immune recovery and reduce risks. The main goal was to see if the transplant was fe…

This early-phase trial tested an experimental drug called CUDC-907 in 26 children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma had stopped responding to standard treatments. The main goal was to find the safest dose and understand side effects. Resea…

This early-phase study tested a special oral powder form of the drug fenretinide in 80 children whose neuroblastoma had come back or not responded to standard treatments. The main goals were to find the safest dose and understand side effects. Researchers also looked at how the d…

This study tested whether a smaller dose of radiation could control high-risk neuroblastoma while reducing long-term side effects. 78 children with high-risk neuroblastoma received reduced-dose radiotherapy. The main goal was to see if the tumor stayed under control at the origin…

This early-phase study tested whether immune cells called natural killer (NK) cells could be safely given to children and young adults with solid tumors that did not respond to standard treatments. Sixteen participants received their own activated NK cells, with or without an imm…

This early-phase study tested a new approach for children with neuroblastoma that did not respond to standard treatments. It used two rapid infusions of a radioactive drug (I-MIBG) to target cancer cells, followed by a stem cell transplant to restore healthy blood cells. The goal…

This early-phase study tested a combination of a radioactive drug (131I-MIBG) and two chemotherapy drugs (irinotecan and vincristine) in 26 children with high-risk neuroblastoma that had come back or not responded to standard treatment. The goal was to find the safest dose of the…

This study tested a new antibody (hu14.18K322A) added to standard chemotherapy for 153 children with high-risk neuroblastoma, a serious nerve tissue cancer. The goal was to see if the combination improves tumor shrinkage and delays the cancer from coming back. While the treatment…

This study tested whether adding bevacizumab (a drug that cuts off tumor blood supply) to standard chemotherapy helps children aged 1–21 with neuroblastoma that came back or didn't respond to treatment. About 225 children took part. The goal was to see if the combination shrinks …

This early-phase study tested an intravenous form of the drug fenretinide in 17 children whose neuroblastoma had come back or didn't respond to standard treatments. The main goals were to find the safest dose and understand side effects. Researchers also looked at how the drug mo…

This study looked at whether analyzing the DNA of a child's tumor can help doctors choose better treatments. 186 children with cancers that came back or didn't respond to standard therapy took part. The goal was to see if this approach is practical and safe, not to directly cure …